Pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors: control of selectivity by a benzyloxy group.
Tripathy, Rabindranath; McHugh, Robert J; Ghose, Arup K; Ott, Gregory R; Angeles, Thelma S; Albom, Mark S; Huang, Zeck; Aimone, Lisa D; Cheng, Mangeng; Dorsey, Bruce D.
Bioorg Med Chem Lett
; 21(24): 7261-4, 2011 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-22061645
Pyrazolone based TGFbetaR1 kinase inhibitors.
3-Aryl-4-(arylhydrazono)-1H-pyrazol-5-ones: Highly ligand efficient and potent inhibitors of GSK3beta.
Discovery of novel 2-substituted-4-(2-fluorophenoxy) pyridine derivatives possessing pyrazolone and triazole moieties as dual c-Met/VEGFR-2 receptor tyrosine kinase inhibitors.
Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.
Development of novel pyrazolone derivatives as inhibitors of aldose reductase: an eco-friendly one-pot synthesis, experimental screening and in silico analysis.
2'-Aryl and 4'-arylidene substituted pyrazolones: As potential α-amylase inhibitors.
Discovery of fluorescent 3-heteroarylcoumarin derivatives as novel inhibitors of anaplastic lymphoma kinase.
Design, Synthesis, and Characterization of Some Hybridized Pyrazolone Pharmacophore Analogs against Mycobacterium tuberculosis.
Design and synthesis of novel selective anaplastic lymphoma kinase inhibitors.
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.